Laverdia Ca-1 (verdinexor) was originally developed by a company working on human cancer treatments. It was discovered that this medicine worked better in dogs than in humans and Anivive Lifesciences, purchased the medication. Since the purchase, they have been working toward full FDA approval.

Published by Amber Drake

Dr. Drake is an award-winning author and well-known cancer specialist in her field. She is best known for her extensive research on canine cancer prevention and nutrition, her dedication to help dogs live a long, happy life, and for teaching veterinary medicine. As the CEO of Canine Companions Co., the Founder of Drake Dog Cancer Foundation and Academy, and the Co-Founder of Preferable Pups, in addition to being a respected figure in the dog world, she has earned the respect of thousands of dog lovers worldwide.